It is hard to think of a less coherent pair of policies: President Trump’s tax policy encourages the very offshoring that his ...

Many established medical therapies to treat myasthenia gravis remain in use, and newer options are available for patients who ...

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

Ticks are spreading globally and bringing familiar conditions such as Lyme disease with them, as well as totally new ones.

The recent formation of the FIBRE Consortium, a collaboration involving Pfizer (NYSE:PFE) and other pharmaceutical partners, ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating ...

Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...